Chidamide Plus DICE Regimen for Patients With Relapse or Refractory B-cell Non-Hodgkin's Lymphoma (NHL)

B-cell Non-Hodgkin's Lymphoma Clinical Trial

Official title:

Study of Chidamide Plus DICE Regimen for Patients With Relapse or Refractory B-cell Non-Hodgkin's Lymphoma (NHL)

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT03105596
• Other study ID #: Chidamide plus DICE
• Status: Not yet recruiting
• Phase: Phase 2
• First received: April 4, 2017
• Last updated: April 9, 2017
• Start date: April 11, 2017
• Est. completion date: September 30, 2019

Study information

• Verified date: April 2017
• Source: Peking University
• Contact: Jun Zhu, MD
• Phone: +86-10-88196596
• Email: zj[@]bjcancer.org
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a prospective phase II clinical trial to observe the efficacy and safety of Chidamide combined with DICE (Dexamethasone, Ifosfamide, Cisplatin and Etoposide) in patients with relapsed or refractory B-cell Non-Hodgkin's Lymphoma (NHL).

Description:

Chidamide，a novel histone deacetylase inhibitor has been approved for the treatment of relapsed or refractory peripheral T-cell lymphoma in China. The aim of this study was to observe the efficacy and safety of Chidamide combined with DICE in patients with relapsed or refractory B-cell Non-Hodgkin's Lymphoma (NHL).

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 46
• Est. completion date: September 30, 2019
• Est. primary completion date: September 30, 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

1. Diagnosed as B-cell Non-Hodgkin's Lymphoma (NHL) according to "2008 WHO classification of tumors of haematopoietic and lymphoid tissues", including Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma, transformed indolent lymphoma, and other subtypes that investigators consider to be appropriate to be enrolled;

2. Patients must have received at least one systemic treatment (including chemotherapy), but did not achieve remission or had relapse after remission;

3. At least one measurable lesion;

4. Age18-65 years, male or female; ECOG performance status 0-1;

5. Without bone marrow involvement. Blood routine test: absolute neutrophil count =1.5 × 109/L, platelet =100 × 109/L, Hb = 90g/L;.

6. Life expectancy no less than 3 months;

7. Not received chemotherapy, targeted medicine or stem cell transplantation 4 weeks before enrollment;

8. Patients have signed the Informed Consent Form.

Exclusion Criteria:

1. Women during pregnancy or lactation, or fertile women unwilling to take contraceptive measures.

2. QTc elongation with clinical significance ( male? 450ms, female? 470ms), ventricular tachycardia, atrial fibrillation, cardiac conducting blockage, myocardial infarction within 1 year, congestive heart failure, symptomatic coronary heart disease that requires treatment;

3. pericardial effusion =10mm sum of echo-free spaces by echocardiography;

4. Patients have undergone organ transplantation;

5. Patients received symptomatic treatment for bone marrow toxicity within 7 days prior to enrollment.

6. Patients with active hemorrhage.

7. Patients with history of thrombosis, embolism, cerebral hemorrhage, or cerebral infarction.

8. Patients with active infection, or with continuous fever within 14 days prior to enrollment.

9. Patients with active infection of HBV, HCV or HIV;

10. Had major organ surgery within 6 weeks prior to enrollment.

11. Impaired liver function ( Total bilirubin ? 1.5 times of normal maximum, ALT/AST? 2.5 times of normal maximum, for patients with infiltrative liver disease ALT/AST ? 5 times of normal maximum), impaired renal function (serum creatinin? 1.5 times of normal maximum).

12. Patients with mental disorders or those do not have the ability to consent.

13. Patients with drug abuse, long term alcoholism that may impact the results of the trial.

14. Patients who have central nervous system involvements;

15. Non-appropriate patients for the trial according to the judgment of the investigators.

Related Conditions & MeSH terms

• B-cell Non-Hodgkin's Lymphoma
• Lymphoma
• Lymphoma, B-Cell
• Lymphoma, Non-Hodgkin

Intervention

Drug:
• Chidamide plus DICE Regimen
Chidamide 20mg orally d1, 4, 8, 11, 15, 18; Dexamethasone 10mg,ivg, d1-4; ifosfamide 1g/m2, ivg, d1-4, given over 4 hours; Mesna 0.4g, 0,4,8,12 hours during Ifosfamide transfusion, ivg, d1-4; Cisplatin 25mg/m2, ivg, d1-4; Etoposide 60mg/m2, ivg. d1-4.

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Peking University

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	objective response rate(ORR)	the total proportion of patients with complete response(CR or CRu)and partial response(PR)	every 6 weeks until 2 years
Secondary	progression-free survival(PFS)	Time from treatment until disease progression or death	2 years
Secondary	events-free survival(EFS)	Time from treatment to disease progression, death, or discontinuation of treatment for any reason	2 years
Secondary	overall survival(OS)	Time from treatment until death from any cause	2 years